SEC Filing Summary for IOVANCE BIOTHERAPEUTICS, INC.

This filing details a transaction by Raj K. Puri, Chief Regulatory Officer of IOVANCE BIOTHERAPEUTICS, INC., involving 15,000 Restricted Stock Units (RSUs) granted on June 16, 2026. These RSUs represent a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining RSUs vesting in eight equal quarterly installments over the subsequent two years. The transaction is reported under Form 4, with a reported post-transaction ownership of 15,000 shares. The price per share was $0.00.